Horizon Therapeutics Public Limited Company
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Horizon Therapeutics Public Limited Company (HZNP), a biopharmaceutical company focused on researching, developing, and commercializing medicines for rare, autoimmune, and inflammatory diseases, operates primarily in the United States with additional presence in Europe; founded in 2005 and formerly headquartered in Dublin, Ireland, with key U.S. operations in Northbrook, Illinois, it functions as a subsidiary of Amgen Inc. following its $27.8 billion acquisition completed in October 2023. The company offers Tepezza (teprotumumab) for thyroid eye disease; Krystexxa (pegloticase) for refractory chronic gout; Uplizna (inebilizumab-cdon) for neuromyelitis optica spectrum disorder; Duexis (ibuprofen/famotidine) and Vimovo (naproxen/esomeprazole magnesium) for arthritis pain and inflammation; Rayos/Lodotra (delayed-release prednisone) for rheumatoid arthritis and other inflammatory conditions; Pennsaid (topical diclofenac) for osteoarthritis pain; and rare disease therapies including Procysbi (cysteamine bitartrate), Ravicti (glycerol phenylbutyrate), and Buphenyl (sodium phenylbutyrate) for urea cycle disorders, alongside Actimmune (interferon gamma) for chronic granulomatous disease and severe malignant osteopetrosis. Recent major developments include Amgen's completion of the transformative acquisition in October 2023 after FTC regulatory clearance, enabling portfolio integration and projected cost savings exceeding $500 million within three years; post-acquisition expansions in manufacturing, such as ongoing enhancements to the Waterford, Ireland facility for rare disease biologics initiated in 2022; and strategic collaborations like the pre-acquisition partnerships with Q32 Bio for autoimmune candidate ADX-914 and Johns Hopkins University for translational research in autoimmunity, alongside Amgen's continued emphasis on international growth for Horizon's rare disease assets including Tepezza, Krystexxa, and Uplizna in 2024-2025.
Company News
Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition
Amgen quarterly profit rises 15% as Horizon deal boosts results
Cramer names biopharma companies to watch as industry mergers start to pile up
5 Biotech Acquisition Targets To Accumulate In 2024
Amgen: Horizon's Pipeline May Be Too Expensive
Amgen completes $27.8 bln Horizon deal
Horizon Therapeutics (HZNP) Up 10.4% Since Last Earnings Report: Can It Continue?
3 Growth Stocks to Buy in September
The FTC cleared Amgen's $27.8 billion Horizon buyout — here's what it means for other massive pharma deals
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
Amgen gets green light from FTC for $27.8B Horizon Therapeutics deal
FTC clears Amgen's $28 billion acquisition of Horizon Therapeutics
Amgen's $27.8 Billion Purchase Of Horizon Therapeutics On After FTC Settlement
Amgen, Horizon Therapeutics Stocks Rise After FTC Settlement Over $27.8 Billion Merger
Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage
FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics
U.S. FTC allows Amgen to move forward with $27.8 bln Horizon deal - CNBC
FTC, Amgen strike deal to allow $27.8 billion Horizon Therapeutics acquisition to move forward
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Is This the Green Light Biotech Stocks Have Been Waiting For?